The CYP26 enzymes have been proposed as anti-cancer drug targets [65] and the increased expression of CYP26A1 and CYP26B1 in colorectal cancer would suggest that these enzymes may be relevant therapeutic targets in this type of tumours. This evidence concerns the gene CYP26A1 and cancer.